araag2/HINT huggingface dataset:
Clinical trial NCT00334685 (phase 2, status: terminated)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: [s,s]-reboxetine + pregabalin, pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1, NCC1(CC(O)=O)CCCCC1
Reason stopped: 
    the data monitoring committee terminated the study on the basis of futility (insufficient
    clinical response).
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have pain present for more than 3 months after the healing of shingles
             skin rash

          -  Patients at screening must have a score >/=40 mm on the pain visual analogue scale

        Exclusion Criteria:

          -  Patients with significant renal and hepatic impairment

          -  Patients with other severe pain, that may impair the self-assessment of the pain due
             to shingles

          -  Patients with clinically abnormal electrocardiogram
Clinical trial NCT00517439 (phase 2, status: completed)
Conditions: hepatitis c, chronic
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4
Drugs: copegus, pegasys, pegasys, ro4588161, ro4588161, ro4588161
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-], CC(C)C(=O)OC[C@]1(O[C@H]([C@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C)N1C=CC(N)=NC1=O)N=[N+]=[N-]
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, 18-65 years of age;

          -  chronic hepatitis C, genotype 1;

          -  chronic liver disease consistent with CHC;

          -  compensated liver disease.

        Exclusion Criteria:

          -  infection with any HCV genotype other than genotype 1;

          -  previous treatment for CHC;

          -  medical condition associated with chronic liver disease other than CHC;

          -  HIV, hepatitis A, hepatitis B infection.
Clinical trial NCT00390221 (phase 2, status: completed)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Multiple Sclerosis (MS) subjects who have a confirmed diagnosis of relapsing-remitting
             MS according to McDonald criteria #1-4 and a baseline Expanded Disability Status Scale
             (EDSS) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria:

               -  Have experienced at least 1 relapse within the 12 months prior to randomization,
                  with a cranial magnetic resonance imaging (MRI) demonstrating lesion(s)
                  consistent with MS , OR

               -  Show evidence of gadolinium-enhancing lesions of the brain on an MRI performed
                  within the 6 weeks prior to randomization.

        Key Exclusion Criteria:

          -  Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS

          -  History of malignancy

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity

          -  History of abnormal laboratory results based on investigator judgment

          -  History of human immunodeficiency virus (HIV) or other immunodeficient conditions

          -  History of drug or alcohol abuse within the 2 years prior to randomization

          -  An MS relapse that has occurred within the 50 days prior to randomization AND/OR the
             subject has not stabilized from a previous relapse prior to randomization

          -  Positive screening for active infection with Hepatitis B virus or Hepatitis C virus

          -  Varicella or herpes zoster virus infection or any severe viral infection within 6
             weeks before Screening

          -  Exposure to varicella zoster virus within 21 days before Screening.

          -  Abnormal blood tests at Screening: Hemoglobin ≤9.0 g/dL, Platelets ≤100 × 10^9/L,
             Lymphocytes ≤1.0 × 10^9/L, Neutrophils ≤1.5 × 10^9/L, alanine aminotransferase/serum
             glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic
             oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase >2 times the upper
             limit of normal (ULN) and serum creatinine >ULN.

        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Clinical trial NCT00210470 (phase 2, status: completed)
Conditions: squamous cell carcinoma of the head and neck
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: cyclophosphamide, indomethacin, zinc, omeprazole
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O, [Zn++].[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O.[H][C@@](O)(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]([H])(O)C([O-])=O, [Na+].OC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologically confirmed (histology) Squamous Cell Carcinoma of the oral cavity,
             oropharynx, hypopharynx, or larynx.

          -  No prior surgery, radiation therapy or chemotherapy of this tumor other than biopsy or
             emergency procedure required for supportive care.

          -  Clinically staged Stage II, III, or IVA cancer, assessed to be surgically resectable
             with curative intent.

          -  Life Expectancy of greater than 6 months

        Exclusion Criteria:

          -  Stage IVB Squamous Cell Carcinoma

          -  Use of any investigational agent within the previous 30 days

          -  Uncontrolled cardiovascular disease

          -  Myocardial infarction within the last 3 months

          -  Abnormal hemoglobin, neutrophil, lymphocyte or platelet counts

          -  Positive for hepatitis B or C or HIV

          -  Evidence of distant metastases

          -  Clinical gastritis or peptic ulcer within the last 6 months

          -  Stroke within the last six months
Clinical trial NCT00491114 (phase 2, status: completed)
Conditions: bladder neoplasms
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Superficial bladder cancer

          -  No prior chemotherapy

        Exclusion Criteria:

          -  Grade 3 tumors

          -  Papillary tumors invading connective tissue

          -  Significant urologic disease, possible interfering with intravesical therapy
Clinical trial NCT00143091 (phase 2, status: terminated)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: cp-316,311, placebo, sertraline
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
Reason stopped: 
    see detailed description for termination reason.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Outpatients with DSM-IV major depressive disorder

        Exclusion Criteria:

          -  Women of child bearing potential
Clinical trial NCT01606384 (phase 2, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: vasopressin v1b receptor antagonist (ssr149415), placebo
SMILES: [H][C@]1(O)CN([C@@]([H])(C1)C(=O)N(C)C)[C@@]1(C(=O)N(C2=C1C=C(Cl)C=C2)S(=O)(=O)C1=C(OC)C=C(OC)C=C1)C1=CC=CC=C1OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria :

          -  Diagnosis of major depressive disorder as defined by the Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition-Text Revision (DSM-IV-TR) and the Mini
             International Neuropsychiatric Interview (MINI) criteria.

        Exclusion criteria:

          -  Outpatients unwilling to be hospitalized a total of 6 nights and 8 days.

          -  Total score of less than 21 (<21) on the 17-item Hamilton Depression Rating Scale
             (HAM-D) at Visit 1 (Day -7) or Visit 5 (Day -1).

          -  Patients whose current depressive episode is diagnosed with psychotic features,
             catatonic features, seasonal pattern or post-partum onset or is secondary to a general
             medical disorder.

          -  Patients with alcohol dependence or abuse or substance dependence or abuse in the past
             12 months according to the MINI, except nicotine or caffeine dependence.

          -  Patients who have used the following prior to entry into Segment B: any antipsychotic
             within 3 months; fluoxetine within 1 month; any monoamine oxidase inhibitor (MAOI)
             within 2 weeks; any other antidepressant, anxiolytic, sedative-hypnotic, or
             mood-stabilizer (lithium, anticonvulsants) within 7 days except permitted concomitant
             medications

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
Clinical trial NCT00259870 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: sb-773812, olanzapine
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Meets the diagnostic criteria for schizophrenia as defined in DSM-IV.

          -  PANSS total score of at least 70 at Screen and Baseline and a minimum score of 4
             (moderate) on at least 2 of the following: conceptual disorganization (P2)
             hallucinatory behaviour (P3) suspiciousness (P6) or unusual thought content (G9) at
             the Screen and Baseline visits

        Exclusion Criteria:

          -  Subjects with a history of epilepsy or other seizure disorder, first episode of
             schizophrenia or other psychotic disorders (e.g. residual type schizophrenia,
             schizophreniform disorder, schizoaffective disorder, delusional disorder, etc.)

          -  Bipolar disorder, a history of substance dependence, or a medical or psychiatric
             disorder that would interfere with the accurate assessment of safety or efficacy are
             not eligible.
Clinical trial NCT02013206 (phase 2, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib [tarceva]
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  histologically documented advanced non-small cell lung cancer (stage IIIB/IV);

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2;

          -  no previous chemotherapy.

        Exclusion Criteria:

          -  previous therapy which acts on Epidermal Growth Factor Receptor (EGFR) axis;

          -  clinical evidence of brain metastasis;

          -  any unstable systemic disease;

          -  unable to take oral medication;

          -  any significant ophthalmological abnormality.
Clinical trial NCT00449423 (phase 2, status: terminated)
Conditions: acute heart failure
ICD codes: I50.811, I50.21, I50.31, I50.813, I50.23, I50.33, I50.41
Drugs: acipimox
SMILES: CC1=[N+]([O-])C=C(N=C1)C(O)=O
Reason stopped: 
    due to slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Acute heart failure

          -  NYHA class III - IV.

          -  ejection fraction <35

        Exclusion Criteria:

          -  Age <18 år or >85 år,

          -  allergy

          -  renal failure

          -  recently developed brady- or tachy-arrythmias

          -  Serious infection

          -  Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular
             heart disease

          -  Recent Myocardial infarction (<6 Weeks)

          -  Pulmonary Wedge pressure >30 mm Hg

          -  diabetes mellitus treated with insulin

          -  peptic ulcer

          -  pregnancy
Clinical trial NCT00002635 (phase 2, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: aminocamptothecin
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(N)C1=C3)C2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed, advanced stages IIB/III/IV cutaneous
        T-cell lymphoma Measurable or evaluable disease required Measurable disease includes: Skin
        disease evaluated by clinical assessment grid method Lesion measurable on imaging (i.e., CT
        measurement of lymph nodes) Pure osteolytic lesion Unidimensional lesion for which a normal
        measurement is available (e.g., mediastinal width on x-ray) Evaluable disease defined as
        malignant disease evident on physical or radiographic exam but not measurable by ruler or
        caliper, i.e.: Pelvic masses Confluent multinodular lung metastases Skin metastases CNS
        metastases eligible if stable for at least 4 weeks following completion of surgery or
        radiotherapy

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At
        least 3 months Hematopoietic: ANC at least 1,500 Platelets at least 100,000 Hepatic:
        Bilirubin no greater than 1.5 mg/dL AST less than 3 times normal Renal: Creatinine no
        greater than 1.5 mg/dL Other: No contraindication to indwelling central venous catheter No
        active infection including HIV No other medical condition that would preclude protocol
        compliance No pregnant or nursing women Adequate contraception required of fertile patients

        PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biological therapy allowed Chemotherapy:
        Prior systemic chemotherapy allowed Patients with more than 1 prior regimen analyzed
        separately At least 4 weeks since chemotherapy (6 weeks since nitrosoureas or mitomycin)
        Endocrine therapy: Not specified Radiotherapy: Prior skin irradiation allowed At least 4
        weeks since wide-field radiotherapy Surgery: Fully recovered from prior surgery Other:
        Prior topical therapy allowed Prior PUVA allowed
Clinical trial NCT01633372 (phase 2, status: active, not recruiting)
Conditions: mpn (myeloproliferative neoplasms)
ICD codes: D47.1
Drugs: itacitinib
SMILES: FC1=C(N=CC=C1C(=O)N1CCC(CC1)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Must be diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy.

          -  Must score at least 1 point on the Dynamic International Prognostic Scoring System
             (DIPSS) for prognostic risk factors and have peripheral blast count <10% at both
             Screening and Baseline hematology assessments.

          -  Subjects must discontinue all drugs used to treat underlying MF disease no later than
             Day -14.

          -  Subjects must have hemoglobin value >/= 8.0g/dL and be willing to receive blood
             transfusions, have a platelet count >/=50x10^9/L and absolute neutrophil count (ANC)
             >/= 1x10^9/L.

          -  Subjects must have palpable spleen or history of splenectomy

          -  Active symptoms at the screening visit

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding, and men and women who cannot comply with
             requirements to avoid fathering a child or becoming pregnant, respectively.

          -  Subjects with impaired liver function, end stage renal disease on dialysis or
             clinically significant concurrent infections requiring therapy.

          -  Subjects with unstable cardiac function or invasive malignancies over the previous 2
             years except treated basal or squamous carcinomas of the skin, completely resected
             intraepithelial carcinoma of the cervix and completely resected papillary thyroid and
             follicular thyroid cancers.
Clinical trial NCT00305331 (phase 2, status: terminated)
Conditions: parkinson's disease, peripheral edema
ICD codes: G20
Drugs: domperidone (drug)
SMILES: ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2
Reason stopped: 
    lack of recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic PD

          -  On a stable medication regimen for at least one month with leg edema occurring after
             the start of pramipexole or ropinirole and the absence of other possible reasons for
             discontinuation of pramipexole or ropinirole treatment (e.g. other adverse effects).

        Exclusion Criteria:

          -  Pregnancy

          -  Breastfeeding

          -  Women of child bearing age not using a reliable method of contraception

          -  Coronary disease, abnormal QT interval on electrocardiogram (EKG)

          -  Diabetes mellitus

          -  Hepatic disease

          -  Alcohol abuse

          -  Renal disease

          -  Edema of one leg only

          -  Presence of other conditions possibly causing leg edema
Clinical trial NCT01007123 (phase 2, status: completed)
Conditions: constipation, chronic constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1, K59.04
Drugs: a3309
SMILES: CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)NCC(O)=O)C3=CC=CC=C3)C=C2S(=O)(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient meets protocol specified criteria for constipation

          -  Patient has successfully completed study requirements with no clinically relevant
             findings for physical exam, ECG, laboratory tests and colonoscopy as applicable

        Exclusion Criteria:

          -  Medical history or medical condition that would not make the patient a good candidate
             for the study or limit the patient´s ability to complete the study

          -  Patient reports loose stools

          -  Patient has IBS with pain/discomfort as predominant symptom

          -  Patient needs medications prohibited as specified in the protocol
Clinical trial NCT00666679 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: comparator: mometasone, comparator: montelukast, comparator: placebo (unspecified)
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, OC(=O)CC1(CC1)CS[C@H](CCC1=CC=CC=C1C(O)(C)C)C1=CC=CC(\C=C\C2=NC3=C(C=CC(Cl)=C3)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has decreased breathing capacity (when not taking asthma medicine) that
             improves after taking a fast-acting asthma inhaler

          -  Within one month of the first study visit, patient has been treated with a fast-acting
             asthma inhaler, and may be treated with a corticosteroid inhaler or an inhaler that
             combines a corticosteroid plus a bronchodilator

        Exclusion Criteria:

          -  Patient is hypersensitive to inhaled beta-agonists, corticosteroids, leukotriene
             antagonists, or any of their components

          -  Has required an oral corticosteroid rescue for worsening asthma during the screening
             period
Clinical trial NCT01189435 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Reason stopped: 
    lack of accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  A history of stage I-IIIB NSCLC

          -  Previously underdone definitive surgery or radiation

          -  Received prior adjuvant treatment or neoadjuvant with erlotinib or gefitinib for a
             total of at least 3 months at any time

          -  Stopped adjuvant erlotinib or neoadjuvant at least 2 months prior to date of first
             imaging demonstrating recurrence

          -  Pathologic evidence of recurrent lung cancer, confirmed at MSKCC EGFR sensitizing
             mutation (point mutation in exons 18 or 21, or deletion in exon 19) must be documented
             in the primary or recurrent tumor

          -  Tissue from their recurrent tumor must be submitted for EGFR mutation testing, and to
             evaluate for the presence of the T790M mutation (results do not need to have been
             reported to be eligible)

          -  Measurable disease by RECIST; if received prior irradiation, then must have a target
             lesion outside the irradiated field

          -  Signed informed consent

          -  Age > or = to 21 years old

          -  Persons of reproductive potential must agree to use an adequate method of
             contraception throughout treatment and for at least 4 weeks after study drug is
             stopped

        Exclusion Criteria:

          -  Prior progressive disease while receiving erlotinib or gefitinib therapy

          -  Patients with known pre-existing interstitial lung disease

          -  Total bilirubin greater than 1.8 mg/dl, excepting patients known to have Gilbert's
             syndrome

          -  AST or ALT greater than five times the upper limit of normal

          -  Pregnant or lactating women

          -  Medically unfit for erlotinib therapy as determined by treating oncologist
Clinical trial NCT01234922 (phase 2, status: terminated)
Conditions: hypertension, unspecified adult solid tumor, protocol specific
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, H01.009, H02.209, H02.009, H02.109, H04.209, H05.409, H10.509
Drugs: lisinopril, losartan potassium, benazepril hydrochloride, ramipril
SMILES: CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, [H][C@@]1(CCC2=CC=CC=C2N(CC(O)=O)C1=O)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC, [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC1=CC=CC=C1)C(=O)OCC
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed solid tumor malignancy
             AND hypertension, defined as a systolic pressure > 130 OR a diastolic pressure > 80

          -  Patients cannot be on active chemotherapy or radiation therapy; start of treatment
             with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy
             or radiation therapy

          -  Creatinine < 2.5

          -  Potassium < ULN

          -  Ability to understand and the willingness to sign a written informed consent document

          -  HIV positive patients are eligible to participate in this study

        Exclusion Criteria:

          -  Patients who are pregnant or nursing due to significant risk to the fetus/infant

          -  Patients who are unable to take oral medications

          -  Patients who are currently taking an ACE-Inhibitor or ARB